Bronchitol Shortlisted for Prestigious Orphan Drug Award
Release Date: 30/06/2014 12:00am
Pharmaceutical development company Pharmaxis is pleased to announce that its product for cystic fibrosis, Bronchitol, has been shortlisted for the prestigious UK Prix Galien Orphan Drug Award.
Prix Galien is an internationally-recognised award, providing global recognition for the technical, scientific and clinical research skills necessary to develop innovative medicines. Moreover, it gives pharmaceutical companies the opportunity to have their products scrutinised by some of the UK medical profession’s most eminent experts, and to be assessed according to the medical, societal and economic benefits they are likely to provide.
The UK Prix Galien judging team is led by Professor Sir Michael Rawlins, President of the Royal Society of Medicine and, until 2013, founding Chairman of the National Institute of Health and Care Excellence. Professor Rawlins is joined by a panel of influential stakeholders from the UK healthcare system.
Categories: News and Media